Profile

unixronin: Galen the technomage, from Babylon 5: Crusade (Default)
Unixronin

December 2012

S M T W T F S
      1
2345678
9101112131415
16171819202122
23242526272829
3031     

Most Popular Tags

Expand Cut Tags

No cut tags
Wednesday, September 6th, 2006 04:15 pm

Auntie Beeb reports that, in the continuing saga of antibiotic misuse and microbial antibiotic resistance, "virtually untreatable" tuberculosis has been encountered in the US, Western Europe, and Africa.

Multi-drug-resistant tuberculosis (MDR-TB), TB strains resistant to two or more of the first-line anti-TB drugs, are already a growing concern.  The WHO estimates there are around 425,000 cases a year, mostly in India' China and the former Soviet Union.  They require treatment with second-line drugs which are more expensive, more toxic, and take longer to work.  Extreme drug-resistant tuberculosis (XDR-TB) strains are resistant not only to all of the first-line TB drugs, but to three or more of the six classes of second-line TB drugs.  Recent studies have found that 4% of MDR-TB cases in the US, 15% in South Korea, and 19% in the former Soviet Union met the XDR-TB criteria.

The article also notes that HIV-positive patients appear to be at particular risk.  52 of 53 XDR-TB patients found in Kwazulu-Natal, South Africa, died within 25 days; 44 of the 53 had been tested for HIV, and all 44 were positive.

Paul Sommerfeld of TB Alert said: "XDR TB is very serious - we are potentially getting close to a bacteria [sic] that we have no tools, no weapons against.

"What this means for the people in southern Africa, who are now becoming susceptible to this where it is appearing, is a likely death sentence.

"For the world as a whole it is potentially extremely worrying that this kind of resistance is appearing.  This is something that I am sure the WHO will be taking very seriously."

Tags:

Reply

This account has disabled anonymous posting.
(will be screened if not validated)
If you don't have an account you can create one now.
HTML doesn't work in the subject.
More info about formatting

If you are unable to use this captcha for any reason, please contact us by email at support@dreamwidth.org